Sana Biotechnology snags Oscine, adding cell therapy leader Steve Goldman to its star-studded staff
Sana Biotechnology CEO Steve Harr began kicking around the idea of acquiring Oscine early on in the companies’ partnership. About a year ago, over dinner with the University of Rochester Medical Center spinout’s CEO and scientific founder, he pulled the trigger.
The partners realized it was “the right thing to do. (And) then it usually takes a lot longer than you hope… to get things done,” Harr said. On Friday, the companies announced they got it done.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.